pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Sep 24·1 min read
save

Radiology practices increasingly develop and market in-house AI, branding themselves as AI-native

Sep 24, 2026·read at STAT ↗Positive

Radiology groups, especially outpatient and teleradiology firms, are moving beyond using third‑party AI tools and are building their own algorithms within the practice.

By keeping development in‑house they can fine‑tune models on their own imaging data, speed up deployment, and claim an “AI‑native” identity to attract referrals and contracts.

This trend reflects a shift where technology creation and clinical service are merging, blurring the traditional separation between software vendors and radiology providers.

Industry observers note that while the promise of AI replacing radiologists has not materialized, the proactive adoption may reshape business models and influence future investment in imaging AI.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: In radiology, AI is blurring the line between technology development and clinical practice”

read at STAT ↗
545 words · retrieved Sep 24
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 13h agoSTAT+: What are the health stakes of the midterms? Policymakers, lobbyists, and experts weigh inSTAT
  • 1d agoSTAT+: Up and down the ladder: The latest comings and goingsSTAT
  • 1d agoHow Election Day can affect your heartSTAT
  • 1d agoAssessing Merck and Moderna’s mRNA cancer vaccineSTAT
  • 1d agoSTAT+: Pharmalittle: We’re reading about AstraZeneca cost-cutting, Sun Pharma facility problems, and moreSTAT